Perspectives of Academic Oncologists About Offering Expanded Access to Investigational Drugs.

ABSTRACT:

Importance

The expanded access (EA) pathway permits patients to be treated with investigational medical products outside clinical trials. Because cancer care is a common indication for which EA is sought and these efforts require physician management, understanding oncologists' perspectives can help illuminate factors influencing patient access.

Objective

To learn how oncologists practicing at academic medical centers (AMCs) perceive EA and their role in offering it.

Design, setting, and participants

This qualitative study used data from semistructured interviews conducted from February 2020 to September 2021 with a purposive sample of oncologists recruited from large, urban AMCs in the northeast United States. Oncologists who had submitted at least 1 single-patient E

SUBMITTER: Gould P 

PROVIDER: S-EPMC9627412 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature